1698878-14-6 Usage
Description
Nampt-IN-1 is a potent inhibitor of nicotinamide phosphoribosyltransferase (Nampt; IC50 = 3.1 nM), which is selective for Nampt over a panel of more than 100 human kinases at 1 μM. It effectively inhibits NAD+ formation and cell proliferation in various cancer cell lines, as well as in an A2780 ovarian carcinoma mouse xenograft model.
Uses
1. Used in Pharmaceutical Industry:
Nampt-IN-1 is used as a co-drug for its potent and selective inhibition of NAMPT, which plays a crucial role in NAD+ formation and cell proliferation. Its ability to inhibit cell growth in a panel of cancer cell lines makes it a promising candidate for the development of anti-cancer therapies.
2. Used in Cancer Research:
Nampt-IN-1 is used as a research tool for studying the role of Nampt in NAD+ formation and its implications in cancer cell proliferation. Its selective inhibition of Nampt over other human kinases allows for a focused investigation of the enzyme's function in various cancer types.
3. Used in Drug Development:
Nampt-IN-1 serves as a lead compound in the development of novel therapeutics targeting Nampt, with potential applications in cancer treatment. Its potent inhibition of NAD+ formation and cancer cell growth makes it a valuable starting point for designing new drugs with improved efficacy and selectivity.
Biochem/physiol Actions
LSN3154567 might be useful in developing a novel cancer therapeutic.
Check Digit Verification of cas no
The CAS Registry Mumber 1698878-14-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,9,8,8,7 and 8 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1698878-14:
(9*1)+(8*6)+(7*9)+(6*8)+(5*8)+(4*7)+(3*8)+(2*1)+(1*4)=266
266 % 10 = 6
So 1698878-14-6 is a valid CAS Registry Number.
1698878-14-6Relevant articles and documents
NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS
-
Page/Page column 29; 30, (2015/04/28)
The present invention provides novel pyridyloxyacetyl tetrahydroisoquinoline compounds that inhibit NAMPT and may be useful in the treatment of cancer.
